Yongyong Ma
Overview
Explore the profile of Yongyong Ma including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
189
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ma Y, Jin Z, Huang J, Zhou S, Ye H, Jiang S, et al.
Oncol Rep
. 2025 Mar;
53(4).
PMID: 40052600
Following the publication of the above paper, a concerned reader drew to the Editor's attention that certain discrete western blot data shown in the RT‑qPCR blots in Figs. 1A and...
2.
Lin Z, Wang Q, Zheng Z, Zhang B, Zhou S, Zheng D, et al.
Front Pharmacol
. 2024 May;
15:1377370.
PMID: 38818376
Significant progress has been achieved in the management of multiple myeloma (MM) by implementing high-dose therapy and stem cell transplantation. Moreover, the prognosis of patients has been enhanced due to...
3.
Zhang T, Lin Z, Zheng Z, Wang Q, Zhou S, Zhang B, et al.
Front Oncol
. 2024 Apr;
14:1322680.
PMID: 38562177
Purpose: To assess the prognostic significance of β2-microglobulin decline index (β2M DI) in multiple myeloma (MM). Methods: 150 MM patients diagnosed with MM were enrolled in this study. Cox proportional...
4.
Wang Q, Zhao M, Zhang T, Zhang B, Zheng Z, Lin Z, et al.
Front Pharmacol
. 2023 Aug;
14:1203125.
PMID: 37608887
One particular type of cellular death that is known as ferroptosis is caused by the excessive lipid peroxidation. It is a regulated form of cell death that can affect the...
5.
Zhang B, Wang Q, Lin Z, Zheng Z, Zhou S, Zhang T, et al.
Front Cell Dev Biol
. 2023 Jun;
11:1198949.
PMID: 37333985
Metabolic reprogramming is an important hallmark of cancer. Glycolysis provides the conditions on which multiple myeloma (MM) thrives. Due to MM's great heterogeneity and incurability, risk assessment and treatment choices...
6.
Zhang B, Wang Q, Zhang T, Zheng Z, Lin Z, Zhou S, et al.
Front Cell Dev Biol
. 2023 May;
11:1159355.
PMID: 37152283
Cuproptosis is a newly identified unique copper-triggered modality of mitochondrial cell death, distinct from known death mechanisms such as necroptosis, pyroptosis, and ferroptosis. Multiple myeloma (MM) is a hematologic neoplasm...
7.
Zhang B, Zhang T, Zheng Z, Lin Z, Wang Q, Zheng D, et al.
Front Oncol
. 2023 Jan;
12:1020566.
PMID: 36713586
Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous disease. Therefore, more reliable biomarkers are required to better predict the prognosis of DLBCL. Cuproptosis is a novel identified form of...
8.
Sun L, Gai Y, Li Z, Zhang X, Li J, Ma Y, et al.
Adv Ther (Weinh)
. 2022 Mar;
4(10).
PMID: 35309962
PET imaging has become an important diagnostic tool in the era of precise medicine. Various pre-targeting systems have been reported to address limitations associated with traditional immuno-PET. However, the application...
9.
Dong R, Jiang S, Chen Y, Ma Y, Sun L, Xing C, et al.
J Interferon Cytokine Res
. 2021 Dec;
41(12):469-476.
PMID: 34935483
Cytokine release syndrome (CRS) is the most common on-target toxicity of chimeric antigen receptor (CAR) T cell therapy. However, the prognostic significance of CRS has not been well elucidated. The...
10.
Sun L, Li Z, Ma Y, Ludwig J, Kim H, Zeng D
Biomed Res Int
. 2021 Jul;
2021:6654262.
PMID: 34212037
Imaging of CD8 receptors on T-cells by positron emission tomography (PET) has been considered a promising strategy for monitoring the treatment response to immunotherapy. In this study, a trial of...